Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis

References

• Bar-Or A. Multiple sclerosis and related disorders: evolving pathophysiologic insights. Lancet Neurol. 2016;15(1):9–11.
   PubMed Web of Science ®Google Scholar
• Comi G, Radaelli M, Sørensen PS. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389(10076):1347–1356.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Thompson AJ, Fox RJ, et al. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389(10076):1357–1366.
   PubMed Web of Science ®Google Scholar
• Auricchio F, Scavone C, Cimmaruta D, et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf. 2017 Dec;16(12):1359–1371.
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Turatti M, Monaco S, et al. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf. 2015 Dec;11(7):157–167.
   Google Scholar
• Guerrero M, Urbano M, Roberts E. Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015). Expert Opin Ther Pat. 2016;26(4):455–470.
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101.
   PubMed Web of Science ®Google Scholar
• Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008 Oct 14;71(16):1261–1267.
   PubMed Web of Science ®Google Scholar
• Kataoka H, Sugahara K, Shimano K, et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol. 2005;2(6):439–448.
   PubMed Web of Science ®Google Scholar
• Sugahara K, Maeda Y, Shimano K, et al. Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol. 2017 Jan;174(1):15–27.
   PubMed Web of Science ®Google Scholar
• Kappos L, Arnold DL, Bar-Or A, et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2016 Oct;15(11):1148–1159.
   PubMed Web of Science ®Google Scholar
• Kappos L, Arnold DL, Bar-Or A, et al. Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Mult Scler. 2017. published on line. 1 September 2017. DOI:10.1177/1352458517728343
   Google Scholar
• Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr;15(4):373–381.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Comi G, Selmaj KW, et al. Ozanimod vs interferon β-1a: clinical and MRI results of RADIANCE part B - A 2-year Phase 3 trial in relapsing multiple sclerosis. Mult Scler. 2017;23(S3):981–982[Abstract].
   Google Scholar
• Comi G, Kappos L, Selmaj KW, et al. Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM). Mult Scler. 2017;23(S3):73–74[Abstract].
   Google Scholar
• Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198–1208.
   PubMed Web of Science ®Google Scholar
• Havrdová E, Achiron A, Coyle P, et al. Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): interim analysis of a phase II extension trial in relapsing-remitting multiple sclerosis. Mult Scler. 2017;23(S3):606[Abstract].
   Google Scholar
• Pan S, Gray NS, Gao W, et al. Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator. ACS Med Chem Lett. 2013;4(3):333–337.
   PubMed Web of Science ®Google Scholar
• Gajofatto A. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. Drug Des Devel Ther. 2017 Nov;2(11):3153–3157.
   Google Scholar
• Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–767.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li DK, Stüve O, et al. Safety and effcacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73(9):1089–1098.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Bar-Or A, Cree B, et al. The EXPAND study results: efficacy of siponimod in secondary progressive multiple sclerosis. Eur J Neurol. 2017;24(suppl 1):44 [Abstract].
   PubMedGoogle Scholar
• Giovannoni G, Bar-Or A, Cree B, et al. The EXPAND study results: safety and tolerability of siponimod in patients with secondary progressive multiple sclerosis. Eur J Neurol. 2017;24(suppl1):495[Abstract].
   PubMedGoogle Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–1828.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–1839.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord. 2017 Oct;10(10):343–359.
   PubMed Web of Science ®Google Scholar
• Margolin DH, Karimi-Anderesi N, Chirieac M, et al. Safety, Tolerability, and pharmacodynamics of intravenous and subcutaneous doses of the anti-CD52 antibody GLD52 in patients with progressive ms: a randomized, controlled, single ascending dose trial. Neurology. 2017;88(16suppl):P5.375[Abstract].
   Google Scholar
• Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2017. published on line 1 November 2017. DOI:10.1177/1352458517740641
   PubMed Web of Science ®Google Scholar
• Herbst R, Wang Y, Gallagher S, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-cd19 antibody. J Pharmacol Exp Ther. 2010;335:213–222.
   PubMed Web of Science ®Google Scholar
• Von Büdingen HC, Palanichamy A, Lehmann-Horn K, et al. Update on the autoimmune pathology of multiple sclerosis: B cells as disease-drivers and therapeutic targets. Eur Neurol. 2015;73:238–246.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study. Neurology. 2014;82:573–581.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Grove R, Austin A, et al. The MIRROR study: a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the safety and MRI efficacy of subcutaneous ofatumumab in subjects with relapsing-remitting multiple sclerosis (RRMS). Neurology. 2014;82(10suppl):S23.006[Abstract].
   PubMedGoogle Scholar
• De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol. 2008;140:635–643.
   PubMed Web of Science ®Google Scholar
• Fox EJ, Lovett-Racke A, Inglese M, et al. Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis. Mult Scler. 2017;23(S3):407[Abstract].
   Google Scholar
• Inglese M, Petracca M, Cocozza S, et al. Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease. Mult Scler. 2017;23(S3):410[Abstract].
   Google Scholar
• Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173:807–817.
   PubMed Web of Science ®Google Scholar
• Kannel K, Alnek K, Vahter L, et al. Changes in blood B Cell-Activating Factor (BAFF) levels in multiple sclerosis: a sign of treatment outcome. PLoS One. 2015 Nov 23;10(11):e0143393.
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Columba-Cabezas S, Serafini B, et al. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol. 2004;148:11–23.
   PubMed Web of Science ®Google Scholar
• Puthenparampil M, Federle L, Miante S, et al. BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset. J Neuroinflammation. 2017 Jan 17;14(1):11. DOI:10.1186/s12974-016-0785-2
   PubMedGoogle Scholar
• Hartung HP, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord. 2010;3:205–216.
   PubMedGoogle Scholar
• Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat Rev Drug Discov. 2017;16:53–70.
   Web of Science ®Google Scholar
• Constantinescu CS, Asher A, Fryze W, et al. Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015 Aug;2(4):e117.
   PubMed Web of Science ®Google Scholar
• Kolbinger F, Huppertz C, Mir A, et al. IL-17A and multiple sclerosis: signaling pathways, producing cells and target cells in the central nervous system. Curr Drug Targets. 2016;17(16):1882–1893.
   PubMed Web of Science ®Google Scholar
• Havrdová E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016 Jul;263(7):1287–1795.
   PubMed Web of Science ®Google Scholar
• López-Herrera G, Vargas-Hernández A, González-Serrano ME, et al. Bruton’s tyrosine kinase: an integral protein of B cell development that also has an essential role in the innate immune system. J Leukoc Biol. 2014 Feb;95(2):243–250.
   PubMed Web of Science ®Google Scholar
• Bender AT, Gardberg A, Pereira A, et al. Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-Cell receptor signaling. Mol Pharmacol. 2017 Mar;91(3):208–219.
   PubMed Web of Science ®Google Scholar
• Hartkamp LM, Fine JS, Van Es IE, et al. BTK inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants. Ann Rheum Dis. 2015 Aug;74(8):1603–1611.
   PubMed Web of Science ®Google Scholar
• Montalban X, Bojanowski J, Martin E, et al. Design of a phase II dose range finding, efficacy and safety study of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients. Mult Scler. 2017;23(S3):324[Abstract].
   Google Scholar
• Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035–1047.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883–897.
   PubMed Web of Science ®Google Scholar
• O’Sullivan C, Schubart A, Mir AK, et al. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016;13:31.
   PubMed Web of Science ®Google Scholar
• Gentile A, Musella A, Bullitta S, et al. Siponimod (BAF312) pre- vents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13(1):207.
   PubMedGoogle Scholar
• Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double- blind, placebo-controlled trial. Lancet. 2016;387(10023):1075–1084.
   PubMed Web of Science ®Google Scholar
• Lehmann-Horn K, Kinzel S, Weber MS. Deciphering the role of B cells in multiple sclerosis-towards specific targeting of pathogenic function. Int J Mol Sci. 2017 Sep 23;18(10):pii: E2048. DOI:10.3390/ijms18102048
   PubMed Web of Science ®Google Scholar
• Kappos L. European study group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon −1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491–1497.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018–2025.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017 Jan 19;376(3):209–220.
   PubMed Web of Science ®Google Scholar
• Stangel M, Kuhlmann T, Matthews PM, et al. Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nat Rev Neurol. 2017 Dec;13(12):742–754.
   PubMed Web of Science ®Google Scholar
• Orack JC, Deleidi M, Pitt D, et al. Concise review: modeling multiple sclerosis with stem cell biological platforms: toward functional validation of cellular and molecular phenotypes in inflammation-induced neurodegeneration. Stem Cells Transl Med. 2015;4(3):252–260.
   PubMed Web of Science ®Google Scholar
• Scolding NJ, Pasquini M, Reingold SC, et al. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017 Nov 1;140(11):2776–2796.
   PubMed Web of Science ®Google Scholar